What stage of chronic kidney disease (CKD) is indicated by a Glomerular Filtration Rate (GFR) of 53?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

GFR of 53 Indicates Stage 3a Chronic Kidney Disease

A glomerular filtration rate (GFR) of 53 mL/min/1.73 m² indicates Stage 3a chronic kidney disease (CKD).

CKD Staging System

The Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines classify CKD into the following stages based on GFR:

Stage Description GFR (mL/min/1.73 m²)
1 Kidney damage with normal or increased GFR ≥90
2 Kidney damage with mild decrease in GFR 60-89
3a Mild to moderate decrease in GFR 45-59
3b Moderate to severe decrease in GFR 30-44
4 Severe decrease in GFR 15-29
5 Kidney failure <15 or dialysis

Clinical Significance of Stage 3a CKD

A GFR of 53 mL/min/1.73 m² falls within the range of 45-59 mL/min/1.73 m², which defines Stage 3a CKD 1. This represents a mild to moderate decrease in kidney function and has important clinical implications:

  • Increased risk for cardiovascular disease events 1
  • Higher risk for progression to more advanced stages of CKD
  • Need for regular monitoring of kidney function
  • Potential need for medication dose adjustments

Monitoring and Management Recommendations

For patients with Stage 3a CKD (GFR 45-59 mL/min/1.73 m²), the following monitoring and management steps are recommended:

  • Monitor GFR and albuminuria every 6-12 months 2
  • Evaluate for anemia, especially as GFR falls below 60 mL/min/1.73 m² 1
  • Assess cardiovascular risk factors and implement appropriate interventions
  • Review medications for potential nephrotoxicity and adjust dosages as needed
  • Control blood pressure, with target guided by presence or absence of albuminuria
  • Manage other modifiable risk factors (diabetes, dyslipidemia)

Importance of Albuminuria Assessment

It's crucial to note that the prognosis and management of Stage 3a CKD are significantly influenced by the presence or absence of albuminuria:

  • Patients with Stage 3 CKD and albuminuria >30 mg/24h have significantly higher cardiovascular and renal risk compared to those without albuminuria 3
  • The 2014 KDIGO guidelines recommend classifying CKD based on cause, GFR category, AND albuminuria category (CGA) 1

Common Pitfalls to Avoid

  1. Relying solely on serum creatinine: Normal serum creatinine values can be misleading, especially in older adults or those with reduced muscle mass. Up to 80.6% of older adults with Stage 3 CKD have creatinine values ≤1.5 mg/dL 4.

  2. Assuming all Stage 3 CKD patients have the same risk: Stage 3a and 3b have different prognoses, with Stage 3b carrying significantly higher risks for adverse renal and cardiovascular outcomes 5.

  3. Overlooking the importance of albuminuria: Even within the same GFR category, the presence of albuminuria substantially increases risk 1.

  4. Dismissing mild GFR reductions in elderly patients: Age-related decline in GFR should not be considered "normal aging" as it still predicts adverse outcomes 1.

In conclusion, a GFR of 53 mL/min/1.73 m² indicates Stage 3a CKD, which requires appropriate monitoring and management to reduce the risk of progression and complications.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Chronic Kidney Disease Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.